UNIV OF IOWA CALGB INSTITUTIONAL GRANT

$148,008U10FY2002CANIH

University Of Iowa, Iowa City IA

Investigators

Linked publications & trials

Paper 29370992 Paper 28976791 Paper 28208174 Paper 26926677 Paper 26056183 Paper 24996441 Paper 24958280 Paper 24838014 Paper 24590644 Paper 24428673 Paper 24419419 Paper 24382782 Paper 24231454 Paper 24097873 Paper 24035029 Paper 23922187 Paper 23890224 Paper 23768804 Paper 23700288 Paper 23129738 Paper 22878823 Paper 22425913 Paper 22421007 Paper 22147942 Paper 22104618 Paper 21849660 Paper 21747089 Paper 21693770 Paper 21693655 Paper 21656739 Paper 21355087 Paper 21321569 Paper 21275630 Paper 21148613 Paper 20688393 Paper 20554945 Paper 20521348 Paper 20368558 Paper 20087228 Paper 19934290 Paper 19652624 Paper 19626540 Paper 19276255 Paper 19255312 Paper 19168670 Paper 19025972 Paper 18978566 Paper 18936475 Paper 18827613 Paper 18824434 Paper 18648813 Paper 18636143 Paper 18559874 Paper 18523220 Paper 18509177 Paper 18388845 Paper 18281659 Paper 18272914 Paper 18234424 Paper 17922873 Paper 17634483 Paper 17607117 Paper 17487729 Paper 17426059 Paper 17404369 Paper 17120198 Paper 17065590 Paper 16985253 Paper 16921041 Paper 16921040 Paper 16909426 Paper 16785067 Paper 16729910 Paper 16118805 Paper 16098244 Paper 15994142 Paper 15923569 Paper 15893009 Paper 15829324 Paper 15767638 Paper 15751020 Paper 15741529 Paper 15572587 Paper 15386381 Paper 15383790 Paper 15301880 Paper 15201999 Paper 15138165 Paper 15084390 Paper 15042678 Paper 14758128 Paper 14717774 Paper 14707498 Paper 14654545 Paper 14630685 Paper 12691141 Paper 12627512 Paper 12621132 Paper 12592330 Paper 12385455

Abstract

DESCRIPTION (adapted from the applicant's abstract): This application is to continue the University of Iowa participation in studies of Cancer and Leukemia Group B. Our goals over the next 5 year period will include: (1) maintenance of accrual to clinical trials of over 100 patients per year (2) add new studies to the CALGB program in the area of: (a) use of Perillyl alcohol as an inhibitor of RAS function both as an antineoplastic in combination with other agents and possibly as a chemopreventive agent, (b) assessment of RAS mutations in the peripheral blood of women who have had chemotherapy as an adjuvant for breast cancer and would be at risk for myelodysplastic syndrome and leukemia, (c) further trials of omega three fatty acids as therapy for cancer cachexia and as an adjuvant to therapy in cancer, (d) continue to develop combined modality therapy for stage 3 and 4 non-small cell lung cancer. In particularly, a pilot at the University of Iowa of Gemcitabine/Carboplatin for non-small cell lung cancer may be able to help CALGB in the future (3) expand CALGB trials to rural hospitals in Iowa where University of Iowa physicians are now providing oncology care (Washington, Iowa; Keosauqua, Iowa; Dubuque, Iowa; Muscatine, Iowa; Fairfield, Iowa; Fort Madison, Iowa)

View original record on NIH RePORTER →